Main image Main image

Cend Therapeutics in the News

December 18, 2019

Harri Jarvelainen, COO of DrugCendR Inc., will meet investors and present data during the 37th JP Morgan Healthcare Conference, Jan 12-16, 2018, in San Francisco. Please contact us to arrange a one-on-one meeting.

October 26, 2019

La Jolla, CA – DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing novel treatment approaches to overcome the barriers of drug delivery in solid tumors, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent related to CendR peptides, further strengthening the company’s intellectual property portfolio beyond the already granted composition of matter patents. U.S. Patent No. 10370245B2 (‘Methods and compositions related to peptides and proteins with c-terminal elements’) has 183 claims and an adjusted expiry in November 2030. The patent is already active in Europe, Japan and China.

“This new patent that provides broad coverage on all peptides with CendR element ensures a robust intellectual property position around the CEND-1 platform technology and the claims granted in this particular patent exemplify the novel mechanistic approach of our science” said Harri Jarvelainen, Chief Operating Officer of DrugCendR Inc. “This development becomes more and more important as we progress with our clinical trial in patients with metastatic pancreatic cancer and prepare to publish the results at a major upcoming scientific meeting next year”.

August 20, 2019

La Jolla, CA, August 5, 2019 — DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr. Daniel Von Hoff will be a clinical advisor to the company. In this role, Dr. Von Hoff will guide the company with its clinical development programs.


Dr. Daniel Von Hoff is Physician in Chief, Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. Dr. Von Hoff has conducted more than 200 clinical trials to date and his clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer, including the gemcitabine and Abraxane® combination therapy. The new treatment approaches he has helped to pioneer have helped tens of thousands of patients with breast, ovarian, prostate, colon, leukemia, skin (advanced basal cell carcinoma) and pancreatic cancer today.


“I am very pleased to be supporting DrugCendR at an especially exciting time in the development program for CEND-1,” said Dr. Von Hoff, adding “Any new therapy that could offer significant benefit to hard-to-treat solid tumors in patients is a welcome lead.”